AngioDynamics Maintains Buy Rating as RECOVER-AV Trial Begins
Recently, H.C. Wainwright reaffirmed a Buy rating for AngioDynamics (NASDAQ: ANGO) and set a price target of $14.00 per share. The spotlight is on the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System, which has launched the RECOVER-AV trial aimed at treating acute pulmonary embolism (PE) in Europe. This initiative is designed to boost the market acceptance of the AlphaVac F1885 System.
Overview of the RECOVER-AV Trial
The RECOVER-AV trial is a forward-looking, single-arm study taking place across several centers in Europe. Its goal is to enroll patients who have been diagnosed with acute, intermediate-risk PE at approximately 20 hospitals.
Main Objectives of the Study
The primary focus of the trial is to evaluate the effectiveness of the AlphaVac F1885 System by looking at changes in the right ventricular/left ventricular (RV/LV) ratio from the start until 48 hours after the procedure. Additionally, the study will assess the safety of the system by monitoring Major Adverse Events (MAEs), considering patient outcomes at 30 days, six months, and one year following the procedure.
Significance of CE Mark Approval
Importantly, the AlphaVac F1885 System has received CE Mark approval in Europe, allowing for the non-surgical removal of thrombi or emboli from pulmonary arteries and for PE treatment. This approval signifies compliance with health, safety, and environmental protection standards necessary for products distributed within the European Economic Area.
Market Impact in the EU
In the European Union, the occurrence of PE is notably higher, especially among patients admitted to emergency departments, compared to the U.S. With around 435,000 PE cases reported each year in the six largest EU countries, successfully introducing the AlphaVac could significantly boost AngioDynamics' revenues in the Med Tech market.
Building Optimism from Prior Trials
H.C. Wainwright's optimism is, in part, based on encouraging results from the APEX-AV trial conducted in the U.S., leading to expectations of positive outcomes from the RECOVER-AV trial in Europe. Anticipated results could foster the adoption of AlphaVac across several EU nations. AngioDynamics is expected to announce its fiscal first-quarter 2025 financial results soon.
Recent Financial Performance Highlights
In more recent news, AngioDynamics reported a slight revenue increase in its latest quarterly financials, reaching pro forma revenue of $71.1 million, primarily thanks to its Med Tech business. Additionally, the company has announced a share buyback plan of up to $15 million.
Looking Ahead: Future Prospects and Product Pipeline
As AngioDynamics forecasts revenues for fiscal 2025 to be between $282 million and $288 million—matching Canaccord Genuity's estimates—the company is carefully managing its financial position. Although Canaccord has lowered its price target, the Buy rating remains intact, highlighting the firm’s ongoing potential.
Concentration on Core Business Strategies
The RECOVER-AV trial marks AngioDynamics' first foray into international research, aiming to evaluate the safety and efficacy of its AlphaVac MMA F1885 System for PE treatment. The company is also focusing its efforts on its core operations by divesting certain business units and ceasing production of non-essential products.
Market Insights and Investor Outlook
With AngioDynamics advancing in the medical device sector through its innovative AlphaVac MMA F1885 System, critical financial metrics and market trends offer valuable insights for potential investors considering the company's growth trajectory. Currently, AngioDynamics' market capitalization is around $310.13 million, indicating a strong position within the industry.
Assessing Financial Viability
Despite facing challenges, such as a negative P/E ratio of -1.68 and an adjusted P/E ratio of -5.86 for the previous fiscal quarter, the company’s financial health appears solid. It holds more cash assets than liabilities, which points to good liquidity and financial agility.
Frequently Asked Questions
What is the RECOVER-AV trial about?
The RECOVER-AV trial is designed to evaluate the safety and efficacy of AngioDynamics' AlphaVac MMA F1885 System for treating acute pulmonary embolism.
What are AngioDynamics' financial targets?
The company expects revenues between $282 million and $288 million for the fiscal year 2025.
What market approval does the AlphaVac F1885 System have?
The AlphaVac F1885 System has received CE Mark certification for the non-surgical removal of thrombi or emboli from pulmonary arteries.
What recent developments have occurred for AngioDynamics?
AngioDynamics recently reported an increase in revenue and announced a share buyback plan, highlighting its positive financial performance.
What is AngioDynamics' position in the market?
With a market capitalization of about $310.13 million, AngioDynamics holds a favorable position in the medical device industry.
